JE
NVO

JMAC Enterprises’s Novo Nordisk NVO Stock Holding History

JMAC Enterprises’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,656
Closed -$370K – 181
2023
Q1 		$370K Hold
4,656
– – 0.09% 132
2022
Q4 		$315K Hold
4,656
– – 0.09% 140
2022
Q3 		$232K Hold
4,656
– – 0.07% 158
2022
Q2 		$259K Buy
+4,656
New +$258K 0.07% 154

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JMAC Enterprises's NVO Position: Q2 2023 in Review

JMAC Enterprises sold out of Novo Nordisk (NVO) in Q2 2023, closing a stake of 4,656 shares — an estimated $370K sold.

JMAC Enterprises first reported a position in NVO in Q2 2022 and held it in 4 quarters. The position peaked at $370K in Q1 2023. 1,197 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

  • JMAC Enterprises reported no remaining Novo Nordisk position as of Q2 2023 after selling out during the quarter.
  • JMAC Enterprises sold 4,656 Novo Nordisk shares in Q2 2023, an estimated $370K.
  • JMAC Enterprises first reported a position in Novo Nordisk in Q2 2022 and held it in 4 quarters.
  • JMAC Enterprises's Novo Nordisk position peaked at $370K in Q1 2023.
  • 1,197 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on JMAC Enterprises's 13F filing for Q2 2023, filed 20 Jul 2023.